Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
36
0
1

Year Published

2020
2020
2021
2021

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 28 publications
references
References 0 publications
2
36
0
1
Order By: Relevance
“…Consistent with our findings, tenofovirdiphosphate has been shown to permanently terminate polymerase extension of nascent RNA when using recombinant RdRp-CoV2 [25]. However, infusion of tenofovir in Vero cell cultures did not inhibit replication of SARS-CoV-2 [26,27], while the use of 3-90 μM of its prodrug TDF yielded a 15-fold reduction of viral genome release [26] . Further, the use of TDF/FTC for treating SARS-CoV-2 infected ferrets led to better clinical scores and lower virus titers in nasal washes compared to a placebo [28].…”
Section: Discussionsupporting
confidence: 88%
“…To investigate this hypothesis, we treated SARS-CoV-2–exposed neutrophils with tenofovir disoproxil fumarate (TDF), an inhibitor of RNA polymerase that has been shown to reduce SARS-CoV-2 replication in Vero cells ( Elfiky, 2020 ; Clososki et al, 2020 ). TDF is a drug of the same class of remdesivir, which is effective in vitro against virus replication and accelerates the recovery of COVID-19 patients ( Yin et al, 2020 ; Beigel et al, 2020 ).…”
Section: Resultsmentioning
confidence: 99%
“…Probably due to the sample size, we cannot see significant results in this regard. Nevertheless, several authors have described the potential activity of tenofovir in SARS-CoV-2 [39] , [40] and specific studies are required to answer this question.…”
Section: Discussionmentioning
confidence: 99%
“… 8 , 9 , 15 , 16 Likewise, TDF, a nucleotide analogue reverse transcriptase inhibitor widely used in the treatment of HIV and Hepatitis B infections, has emerged as a new investigative agent against COVID-19. It is from the same class as remdesivir, a novel nucleotide analogue that has activity against SARS-CoV-2 in vitro 17 and has been recommended for hospitalized patients with severe COVID-19 in many guidelines. 18 However, no ARV has demonstrated clinical impact so far.…”
Section: Discussionmentioning
confidence: 99%
“…Considerando experiências anteriores, a expectativa na área médica é de que a produção e distribuição em grande escala e disponibilidade de uma vacina para os países em desenvolvimento é algo que poderá demorar de um a três anos, segundo admite a própria Organização Mundial da Saúde (Le et al, 2020). Paralelamente, o desenvolvimento de novos fármacos para o tratamento da doença pode tornar possível a convivência com o vírus causador da Covid-19 (Clososki et al, 2020).…”
Section: Introductionunclassified